Miami Cancer Institute Precision Oncology

Given the increasing discovery of oncogenic-driven tumors, targeted treatments with novel agents have transformed patient outcomes. Clinical decision making and management therefore have become more complex. This online course has been designed to provide an overview on precision medicine and an update on evolving molecular-based system therapies. 

Topics include:

  • Precision Oncology in Brain Metastases: Past, Present and Future
  • Precision Medicine: Management of Ovarian Cancer
  • Targeted Therapy for ER+/HER2-MBC: CDK4/6 Inhibition and Beyond

Educational Grants

Baptist Health gratefully acknowledges the educational grants provided by Coherus Biosciences and Deciphera Pharmaceuticals for this activity.

Target Audience

Hematologists, oncologists, pathologists, radiation oncologists, nurses, pharmacists, pharmacy technicians, palliative care staff and other allied healthcare members interested in the treatment of patients with solid tumor malignancies.

Learning Objectives

  • Explain the evolving therapeutic strategies for the treatment of solid tumor malignancies including new molecular and targeted treatments in development. 
  • Utilize diagnostic tests and molecular profiling to determine the role of targeted therapy treatments in solid tumor malignancies.
Additional information
Bibliography: 
  • Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020). Overcoming endocrine resistance in breast cancer. Cancer cell, 37(4), 496-513.
  • Metcalfe, C., Friedman, L. S., & Hager, J. H. (2018). Hormone-targeted therapy and resistance. Annual Review of Cancer Biology, 2, 291-312.
  • McCartney, A., Migliaccio, I., Bonechi, M., Biagioni, C., Romagnoli, D., De Luca, F., ... & Di Leo, A. (2019). Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice. Frontiers in oncology, 9, 666.
  • Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., ... & DiSilvestro, P. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495-2505.
  • Miller, R. E., Leary, A., Scott, C. L., Serra, V., Lord, C. J., Bowtell, D., ... & Yates, L. R. (2020). ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology, 31(12), 1606-1622.
  • González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., ... & Monk, B. J. (2019). Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 381(25), 2391-2402.
  • Magnuson, W. J., Lester-Coll, N. H., Wu, A. J., Yang, T. J., Lockney, N. A., Gerber, N. K., ... & Chiang, V. L. (2017). Management of brain metastases in tyrosine kinase inhibitor–naïve epidermal growth factor receptor–mutant non–small-cell lung cancer: a retrospective multi-institutional analysis. Journal of clinical oncology, 35(10), 1070-1077.
  • Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., ... & Ramalingam, S. S. (2018). Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. New England journal of medicine, 378(2), 113-125.
  • Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S. H. I., Pacheco, J. M., ... & Spira, A. I. (2022). Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation. New England Journal of Medicine, 387(2), 120-131.
Course Summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
  • 1.25 Florida Board of Pharmacy
Course opens: 
03/01/2023
Course expires: 
02/28/2025
Cost:
$9.95

Manmeet S. Ahluwalia, M.D., MBA
Fernandez Family Foundation Endowed Chair in Cancer Research 
Chief of Medical Oncology 
Chief Scientific Officer & Deputy Director
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida

John P. Diaz, M.D.
Chief of Gynecologic Oncology
Medical Director of Robotic Surgery, Baptist Health South Florida
Medical Director of Baptist Health Surgical Center, Plantation
Lead Physician for Clinical Research, Gynecologic Oncology Clinical Trials
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida

Reshma Mahtani, D.O.
Chief of Breast Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida
                
Manmeet S. Ahluwalia, M.D., MBA, FASCO, conference director and faculty for this educational activity, is a consultant with Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Caim Therapeutics, Theraguix, Anheart Therapeutics and Varian Medical Systems. He is also a researcher for AstraZeneca, Bayer, BMS, Incyte, Merck, Mimivax, Novocure and Pharmacyclics; is a shareholder with Mimivax, Cytodyn, MedInnovate Advisors LLC; and on the scientific advisory board for Cairn Therapeutics, Pyramid Biosciences and Modifi Biosciences. Dr. Ahluwalia indicated that the presentation or discussion will include off-label or unapproved product usage.  

Reshma Mahtani, D.O., faculty for this educational activity, is a consultant for Agendia, Amgen, AstraZeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Lilly, Merck, Novartis, Pfizer, Puma, Seagen, Sanofi, Sermonix and Stemline. Dr. Mahtani, is an advisor for Amgen, AstraZeneca and Sanofi and has indicated that the presentation or discussion will include off-label or unapproved product usage. 

John P. Diaz, M.D., faculty for this educational activity, is a researcher for Merck and AstraZeneca, a consultant for Dysis, an advisor for Seagen and a member of the speakers’ bureau with AstraZeneca and Merck. Dr. Diaz has indicated that the presentation or discussion will not include off-label or unapproved product usage. 

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.

*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
  • 1.25 Florida Board of Pharmacy

Price

Cost:
$9.95
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome		Microsoft Edge
Microsoft Edge		Safari
Safari		Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.